Florbetapir (18F)
Clinical data | |
---|---|
Pronunciation | flor bay' ta pir |
Trade names | Amyvid |
Other names | 18F-AV-45, florbetapir-fluorine-18, Florbetapir F 18[1] (USAN US) |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
License data |
|
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
JSmol) | |
| |
|
Florbetapir (18F), sold under the brand name Amyvid, is a
One review predicted that amyloid imaging is likely to be used in conjunction with other markers rather than as an alternative.[9]
Development
Since the disease was first described by Alois Alzheimer in 1906, the only certain way to determine if a person indeed had the disease was to perform a biopsy on the patient's brain to find distinctive spots on the brain that show the buildup of amyloid plaque. Doctors must diagnose the disease in patients with memory loss and dementia based on symptoms, and as many as 20% of patients diagnosed with the disease are found after examination of the brain following death not to have had the condition. Other diagnostic tools, such as analysis of cerebrospinal fluid, magnetic resonance imaging scans looking for brain shrinkage and PET scans looking at how glucose was used in the brain, had all been unreliable.[10][11]
The development of florbetapir built on research done by William Klunk and Chester Mathis who had developed a substance they called
Initial tests in 2007 on a patient at
Validation by autopsy
In order to confirm if the isotope was accurate in detecting Alzheimer's, an advisory committee at the
In results presented in July 2010, the company showed that for 34 out of the 35 hospice patients who had been scanned, the initial scan results were confirmed when pathologists counted plaque under a microscope and when a computerized scan of the plaque was performed on material from the autopsied brain.[14] The findings required review by the FDA to confirm their reliability as a means of diagnosing the disease. Once confirmed, the technique provided a means to reliably diagnose and monitor the progress of Alzheimer's and allowed potential pharmaceutical treatments to be evaluated.[10]
In a study published in January 2011 in the
Approval by FDA
On January 20, 2011, an FDA advisory committee unanimously recommended that Avid's PET scan technique be approved for use. The advisory committee included a qualification requiring Avid to develop clear guidelines establishing when the tests had spotted enough of the amyloid plaque to make a diagnosis of Alzheimer's, a task that Avid CEO Daniel M. Skovronsky stated could be resolved in several months.[16]
Acquisition by Eli Lilly
Avid Radiopharmaceuticals was based at the University City Science Center research campus in Philadelphia, Pennsylvania. The company was the first to bring to market an FDA-approved method that could directly detect the amyloid deposition hallmark pathology of Alzheimer's disease.
Eli Lilly and Company announced on November 8, 2010, that they would acquire Avid for $800 million, $300 million up front and the balance paid later.[17] Dr. Skovronsky joined the executive committee following the acquisition.[18]
References
- ^ "Statement on a Nonproprietary Name Adopted by the USAN Council - FLORBETAPIR F 18" (PDF). United States Adopted Name (USAN) Drug Finder. American Medical Association. Retrieved 18 March 2022.
- ^ "Amyvid- florbetapir f 18 injection, solution". DailyMed. Retrieved 12 January 2021.
- ^ "Amyvid EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 12 January 2021.
- ^ "Drug Approval Package: Amyvid (florbetapir F 18) NDA 202008". U.S. Food and Drug Administration. 3 May 2012. Retrieved 12 October 2021.
- PMID 19834448.
- PMID 20641982. Retrieved 2010-06-24.
- ^ Kolata G (June 23, 2010). "Promise Seen for Detection of Alzheimer's". The New York Times. Archived from the original on 28 June 2010. Retrieved June 23, 2010.
- ^ PMID 20501908.
- Lay summary in: "FDA Approves PET Imaging Agent for Alzheimer's Evaluation". Diagnostic Imaging. April 9, 2012.
- PMID 19847050.
- ^ a b c d e f Kolata G (23 June 2010). "Promise Seen for Detection of Alzheimer's". The New York Times. Retrieved 23 June 2010.
- ^ a b "Avid Radiopharmaceuticals Initiates First Phase II Trial Of Novel Compound For Imaging Alzheimer's Disease". Medical News Today. 11 June 2008. Retrieved 23 June 2010.
- ^ "Phila. start-up developing a way to test for Alzheimer's, Avid Radiopharmaceuticals has raised $26 million in new venture financing. Seeking a test for Alzheimer's". The Philadelphia Inquirer. 9 May 2007. Retrieved 23 June 2010.
- ^ "Avid Radiopharmaceuticals Selected to Receive Seed Funding from BioAdvance; Funds to Be Used to Develop Molecular Imaging Tools for Alzheimer's Disease". Business Wire. 5 January 2005. Retrieved 23 June 2010.
- ^ Kolata G (12 July 2010). "New Scan May Spot Alzheimer's". The New York Times. Retrieved 14 July 2010.
- ^ Kolata G (18 January 2011). "Two Tests Could Aid in Risk Assessment and Early Diagnosis of Alzheimer's". The New York Times. Retrieved 19 January 2011.
- ^ Kolata G (30 January 2011). "F.D.A. Sees Promise in Alzheimer's Imaging Drug". The New York Times. Retrieved 20 January 2011.
- ^ "Lilly Snags Avid Radiopharma". Forbes. 8 November 2010. Retrieved 8 November 2010.
- ^ "Daniel M. Skovronsky, M.D., Ph.D. | Eli Lilly and Company". www.lilly.com. Retrieved 2020-07-17.
External links
- "Florbetapir F-18". Drug Information Portal. U.S. National Library of Medicine.